Vita Life Sciences Ltd banner

Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 2.6 AUD -3.7% Market Closed
Market Cap: AU$142.1m

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is hidden AUD. Compared to the current market price of 2.6 AUD, Vita Life Sciences Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
145.4m AUD 1.7 15.6 9.2 9.2
US
Eli Lilly and Co
NYSE:LLY
992.9B USD 15.2 48.1 32.4 34.5
US
Johnson & Johnson
NYSE:JNJ
575.5B USD 6.1 21.5 14.9 18.3
CH
Roche Holding AG
SIX:ROG
283.1B CHF 4.6 30 12.7 14.8
CH
Novartis AG
SIX:NOVN
231.6B CHF 5.3 21.3 13.2 16.9
UK
AstraZeneca PLC
LSE:AZN
215.3B GBP 5.2 32 15.3 22.4
US
Merck & Co Inc
NYSE:MRK
291.1B USD 4.5 16 10 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 10 11.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
153.9B USD 2.5 19.8 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123.2B USD 2.6 17.5 6.8 8.8
P/E Multiple
Earnings Growth PEG
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 23.5
15.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
CH
Novartis AG
SIX:NOVN
21.3
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32
38%
0.8
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.8
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 42.3
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.4
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
CH
Novartis AG
SIX:NOVN
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10
7%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBIT: 90.3
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.5
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
CH
Novartis AG
SIX:NOVN
16.9
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.4
23%
1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.9
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-6%
N/A